Shareholdings
| Concept |
As at 2024-03-31 |
As at 2024-03-31 |
As at 2024-03-31 |
As at 2024-03-31 |
As at 2024-03-31 |
As at 2024-03-31 |
As at 2024-03-31 |
As at 2024-03-31 |
As at 2024-03-31 |
As at 2024-03-31 |
As at 2024-03-31 |
As at 2023-03-31 |
As at 2023-03-31 |
As at 2023-03-31 |
As at 2023-03-31 |
As at 2023-03-31 |
As at 2023-03-31 |
As at 2023-03-31 |
As at 2023-03-31 |
As at 2023-03-31 |
As at 2023-03-31 |
As at 2023-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholdings | ||||||||||||||||||||||
| Second largest holding company | ||||||||||||||||||||||
| Details of specified investment shares held for purposes other than pure investment | ||||||||||||||||||||||
| Issue |
㈱クスリのアオキホールディングス
|
澁谷工業㈱
|
参天製薬㈱
|
久光製薬㈱
|
㈱ファルコホールディングス
|
第一三共㈱
|
大塚ホールディングス㈱
|
㈱北國フィナンシャルホールディングス
|
㈱サンウェルズ
|
明治ホールディングス㈱
|
小野薬品工業㈱
|
— | — | — | — | — | — | — | — | — | — | — |
| Number of shares |
1,260,000
xbrli:shares
|
21,422
xbrli:shares
|
31,295
xbrli:shares
|
76,366
xbrli:shares
|
51,778
xbrli:shares
|
236,040
xbrli:shares
|
1,600,000
xbrli:shares
|
16,621
xbrli:shares
|
— |
15,404
xbrli:shares
|
159,365
xbrli:shares
|
159,365
xbrli:shares
|
17,801
xbrli:shares
|
420,000
xbrli:shares
|
16,621
xbrli:shares
|
1,600,000
xbrli:shares
|
236,040
xbrli:shares
|
15,000
xbrli:shares
|
— |
45,907
xbrli:shares
|
7,702
xbrli:shares
|
74,042
xbrli:shares
|
| Number of shares (Not disclosed as below threshold) | — | — | — | — | — | — | — | — |
*
|
— | — | — | — | — | — | — | — | — |
*
|
— | — | — |
| Carrying amount |
3,986,000,000
JPY
|
75,000,000
JPY
|
48,000,000
JPY
|
303,000,000
JPY
|
121,000,000
JPY
|
1,127,000,000
JPY
|
10,096,000,000
JPY
|
84,000,000
JPY
|
— |
52,000,000
JPY
|
391,000,000
JPY
|
440,000,000
JPY
|
44,000,000
JPY
|
2,818,000,000
JPY
|
68,000,000
JPY
|
6,724,000,000
JPY
|
1,138,000,000
JPY
|
38,000,000
JPY
|
— |
90,000,000
JPY
|
48,000,000
JPY
|
279,000,000
JPY
|
| Carrying amount (Not disclosed as below threshold) | — | — | — | — | — | — | — | — |
*
|
— | — | — | — | — | — | — | — | — |
*
|
— | — | — |
| Purpose of shareholding, overview of business alliance, quantitative effects of shareholding and reason for increase in number of shares |
・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１・株式分割
|
・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１・株式累積投資
|
・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１
|
・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１・取引先持株会会員
|
・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１・株式累積投資
|
・良好な取引関係の維持発展・当社グループの取引先 ・検証実施(注)１
|
・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１
|
・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１
|
・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１
|
・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１・株式分割
|
・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１
|
— | — | — | — | — | — | — | — | — | — | — |
| Whether issuer of aforementioned shares holds reporting company's shares |
無
|
無
|
無
|
有
|
無
|
有
|
無(注)３
|
無
|
無
|
無(注)３
|
有
|
— | — | — | — | — | — | — | — | — | — | — |